A local court has turned down Medytox’s appeal for suspending the execution of the government’s order to stop making and selling its botulinum product, Meditoxin.
The Daejeon District Court recently dismissed Medytox’s application for suspending the execution of the administrative order to that effect issued by the head of the Daejeon branch of the Ministry of Food and Drug Safety, according to industry sources on Wednesday.
During a trial on Tuesday, the judge reviewed both sides of the allegations and reportedly said there was little reason to stop the administrative discipline by the food and drug ministry’s Daejeon branch.
Earlier, the food and drug safety ministry suspended the manufacturing, selling, and using of Meditoxin due to suspicions that the company used unauthorized ingredients and faked test results to obtain approval for shipments dozens of times. The prosecution indicted Medytox CEO Jung Hyun-ho and the head of the Medytox’s plant on charges of violating the Pharmaceutical Affairs Act and the obstruction of justice.
In response, Medytox filed an administrative suit against the ministry, saying Meditoxin products at issue were produced between December 2012 and June 2015 and no longer existed. The company also requested the Daejeon court to suspend the ministry’s execution of the administrative order.
<© Korea Biomedical Review, All rights reserved.>